Psychiatry research case reports最新文献_第7页

Efficacy of combined theta burst stimulation (TBS) and intranasal esketamine in an ECT-resistant depressive patient: A case report θ爆发刺激（TBS）和鼻内注射埃斯卡他敏联合疗法对一名电痉挛疗法耐药的抑郁症患者的疗效：病例报告

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-02-11 DOI: 10.1016/j.psycr.2025.100250

Álvaro Moleón-Ruiz , Paloma Álvarez de Toledo , Inmaculada Pérez , Javier Narbona , Luis Gutiérrez-Rojas , Manuela Martín-Bejarano

{"title":"Efficacy of combined theta burst stimulation (TBS) and intranasal esketamine in an ECT-resistant depressive patient: A case report","authors":"Álvaro Moleón-Ruiz , Paloma Álvarez de Toledo , Inmaculada Pérez , Javier Narbona , Luis Gutiérrez-Rojas , Manuela Martín-Bejarano","doi":"10.1016/j.psycr.2025.100250","DOIUrl":"10.1016/j.psycr.2025.100250","url":null,"abstract":"<div><div>Treatment-resistant depression (TRD) presents significant clinical challenges, often requiring innovative approaches beyond conventional pharmacotherapy and psychotherapy. This case report explores the efficacy of combined repetitive Transcranial Magnetic Stimulation (rTMS) and intranasal esketamine (IN-ESK) in a patient with TRD.</div><div>A female in her 60 s with a prolonged history of recurrent endogenous-type depressive disorder presented with severe depressive symptoms, including suicidal ideation, despite numerous pharmacotherapies, psychotherapies, and 17 sessions of ECT. The patient underwent a treatment regimen combining rTMS and IN-ESK. rTMS involved continuous theta burst stimulation (cTBS) to the right dorsolateral prefrontal cortex (DLPFC) and intermittent theta burst stimulation (iTBS) to the left DLPFC. IN-ESK was administered at 56 mg for the first two sessions and 84 mg for subsequent sessions over four weeks. The combined treatment resulted in a substantial reduction in depressive and anxiety symptoms. Pre-treatment scores on the Patient Health Questionnaire-9 (PHQ-9) and Hamilton Depression Rating Scale (HDRS) indicated severe depression (PHQ-9 score of 24) and moderate depression (HDRS score of 19). Post-treatment assessments showed significant improvement, with PHQ-9 scores decreasing to 7 (mild depression) and HDRS scores dropping to 5 (remission). Suicidal ideation and anxiety levels also showed marked reduction, with the Hamilton Anxiety Scale (HAS) score decreasing from 20 to 10. The combination of rTMS and IN-ESK demonstrated significant therapeutic benefits in this ECT-resistant depressive patient. This case highlights the potential of this combined modality as a promising treatment for TRD, warranting further research to understand the underlying mechanisms and long-term efficacy.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100250"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143421028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-03-10 DOI: 10.1016/j.psycr.2025.100258

İrem Cihanyurdu Erdem , Ayşe Burcu Erdoğdu Yıldırım , Neşe Perdahlı Fiş

引用次数: 0

Case report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis 病例报告：32岁晚期酒精性肝硬化女性患者经mdma辅助治疗耐受良好

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-02-25 DOI: 10.1016/j.psycr.2025.100252

Elias Kraus , Stephanie Suter , Margit Proescholdt , Felix Müller , Matthias E. Liechti , Markus Heim , Undine Lang , Marc Vogel

{"title":"Case report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis","authors":"Elias Kraus , Stephanie Suter , Margit Proescholdt , Felix Müller , Matthias E. Liechti , Markus Heim , Undine Lang , Marc Vogel","doi":"10.1016/j.psycr.2025.100252","DOIUrl":"10.1016/j.psycr.2025.100252","url":null,"abstract":"<div><h3>Background</h3><div>Several studies have examined 3,4-Methylenedioxymethamphetamine (MDMA) as a therapeutic adjunct in the treatment of post-traumatic stress disorders (PTSD). Alcohol use disorder (AUD) is common in patients with PTSD and can lead to alcohol-induced liver cirrhosis. There is a concern that MDMA, which is associated with liver toxicity in some cases, may not be tolerated by PTSD-patients with pre-existing, alcohol-induced liver cirrhosis. There is currently no data available to asses this risk.</div></div><div><h3>Case presentation</h3><div>We present the case of a 32-year old female patient with post-traumatic stress disorder and advanced alcohol-induced liver cirrhosis who received MDMA-assisted therapy. MDMA was administered twice (50 mg, 100 mg) over the course of two weeks. Apart from one episode of vomiting and the subjective sensation of numb and swollen fingers (without clinical findings) under the influence of MDMA, there were no adverse effects. Laboratory values did not show any signs of acute MDMA-induced liver injury.</div></div><div><h3>Conclusions</h3><div>There were no signs of acute MDMA-induced liver injury in our patient, despite advanced, pre-existing liver cirrhosis due to alcohol use. This finding is on a case level and cannot be generalized, but is encouraging for future research in patients with liver disorders. Further research is necessary to confirm the safety of MDMA-assisted therapy in patients with pre-existing, alcohol-induced liver cirrhosis.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100252"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143552471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A pharmacotherapeutic and neuroimaging case study of maladaptive daydreaming 不适应白日梦的药物治疗和神经影像学案例研究

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-01-26 DOI: 10.1016/j.psycr.2025.100249

Daniel Mamah, ShingShiun Chen, Ayleen Gomez-Lopez, Samantha Alexander

{"title":"A pharmacotherapeutic and neuroimaging case study of maladaptive daydreaming","authors":"Daniel Mamah, ShingShiun Chen, Ayleen Gomez-Lopez, Samantha Alexander","doi":"10.1016/j.psycr.2025.100249","DOIUrl":"10.1016/j.psycr.2025.100249","url":null,"abstract":"<div><h3>Background</h3><div>Maladaptive daydreaming (MD) is an underreported mental health condition involving prolonged, vivid fantasizing, associated with significant functional impairment or disability. The underlying neurobiology of MD is unknown, and there have been no prior neuroimaging studies in affected individuals.</div></div><div><h3>Case presentation</h3><div>A twenty-year-old woman with a history of depression and obsessive-compulsive disorder reported experiencing intense and highly distracting daydreams, exacerbated by stress and resulting in an inability to complete her studies. We describe her clinical presentation, treatment and symptom response over 120 weeks. Depression was largely treatment-resistant with antidepressants, and improvement with lamotrigine (Lamictal) augmentation was limited by poor tolerance. Antipsychotic medications (lurasidone, risperidone (Risperdal) and aripiprazole) resulted in a rapid reduction or cessation of daydreaming, and dopaminergic medications (lisdexamfetamine and bupropion) resulted in substantially increased time spent daydreaming. The patient underwent Magnetic Resonance Imaging (MRI) using a 3 Tesla scanner, and the brain's cortical thickness and functional connectivity networks were assessed and compared to a matched population of healthy individuals. We found regions of cortical thinning in the left hemisphere, primarily in the middle temporal cortex. The left default mode and cingulo-opercular networks, and the salience network bilaterally, were enlarged compared to the general population. In contrast, the left frontoparietal network was smaller.</div></div><div><h3>Conclusion</h3><div>A hyperdopaminergic state may be involved in some cases of MD. Altered development of the left brain may underlie the capacity for prolonged, vivid daydreaming. Future studies in larger patient populations are needed to validate findings.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100249"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Testosterone use as a treatment of cachexia in patients with schizophrenia: A case report 使用睾酮治疗精神分裂症患者的恶病质：一例报告

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-05-01 DOI: 10.1016/j.psycr.2025.100262

Fatima Al Quraish, Naista Zhand

{"title":"Testosterone use as a treatment of cachexia in patients with schizophrenia: A case report","authors":"Fatima Al Quraish, Naista Zhand","doi":"10.1016/j.psycr.2025.100262","DOIUrl":"10.1016/j.psycr.2025.100262","url":null,"abstract":"<div><h3>Introduction</h3><div>Aberrant feeding behaviours in schizophrenia, which could result in cachexia and starvation status, have been described in the literature. Testosterone is used as an adjunct treatment in patients with cancer and HIV-induced cachexia to increase lean body mass, and could be considered as a potential option for management of cachexia due to other causes such as schizophrenia. In this case report, we describe use of adjunct testosterone in a patient with schizophrenia and significant weight loss.</div></div><div><h3>Method</h3><div>We present a case report of a patient with chronic schizophrenia who was admitted to our Schizophrenia inpatient unit with relapse of psychosis, catatonia and significant weight loss/malnutrition. His weight on admission was 38.2 kg with a body mass index (BMI) of 14. He was treated with antipsychotic medications and ECT, to which he responded favourably. However, after 6 months in hospital and despite improvement of his mental status, his oral intake and weight were still suboptimal. He was started on intramuscular testosterone to enhance muscle mass, address low weight and improve energy.</div></div><div><h3>Results</h3><div>An improvement in energy, appetite and weight was observed. Following 13 weeks of regular treatment with testosterone, his weight increased from 45 kg to 52 kg, correlating to a 15.5% increase in total body weight. There were no adverse effects.</div></div><div><h3>Conclusions</h3><div>Supplementary testosterone can be considered as an adjunct option for treatment of persistent cachexia in patients with schizophrenia who continue to struggle with low body weight and low energy, despite optimized psychiatric treatment.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100262"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143948316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early-onset Kleine-Levin syndrome in adolescent: A case report and review of literature 青少年早发型克莱因-莱文综合征：病例报告和文献综述

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-02-25 DOI: 10.1016/j.psycr.2025.100253

Yuejiao Ma, Jianping Lu

引用次数: 0

Qualitative analysis of a patient's experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs 对一名患者在氯胺酮辅助心理治疗中治疗物质使用障碍的定性分析：与十二步方案的经验协同作用

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-03-24 DOI: 10.1016/j.psycr.2025.100259

Dan Petrovitch , Jacob Spinks , Hannah B. Yoo , Lindsay Kerr , Joshua Willms , Mary Katherine Jurek , Rachel Wanzor-Box , Andrew K. Littlefield , Ben McCauley

{"title":"Qualitative analysis of a patient's experience of ketamine-assisted psychotherapy for substance use disorder: Empirical synergies with twelve-step programs","authors":"Dan Petrovitch , Jacob Spinks , Hannah B. Yoo , Lindsay Kerr , Joshua Willms , Mary Katherine Jurek , Rachel Wanzor-Box , Andrew K. Littlefield , Ben McCauley","doi":"10.1016/j.psycr.2025.100259","DOIUrl":"10.1016/j.psycr.2025.100259","url":null,"abstract":"<div><div>Ketamine has demonstrated early promise for treating substance use disorder (SUD). Despite the emerging evidence for ketamine-based approaches for SUD, little has been published on the integration of ketamine-assisted psychotherapy (KAP) with existing pharmacologic, psychosocial, and peer-support approaches to treatment and recovery, including 12-step programs. Here, we present the case of a 28-year-old female treated for alcohol and opioid use disorder. We executed an inter-clinic, collaborative treatment plan that involved a psychedelic, ketamine-based regimen in combination with extant psychosocial and 12-step-based treatments for SUD. Qualitative analysis of the patient's lived experience suggested that ketamine played an important role in her self-reported experience of recovery, as she attributed psychological and spiritual changes to ketamine treatments. Specifically, this report highlights the extent to which the patient's ketamine-induced experiences overlapped with the 12 steps—specifically with respect to recognizing the seriousness of her SUD, committing to change, developing spirituality, and repairing interpersonal relationships, among other points of interface that could be useful for clinicians treating 12-step-involved SUD patients with ketamine.</div></div><div><h3>Clinical impact statement</h3><div>This article analyzed the correspondence between a patient's lived experience of a ketamine-based treatment regimen for addiction and the 12 steps. It suggests notable points of overlap between her ketamine experiences and the 12 steps, which could be useful to clinicians treating 12-step involved patients with ketamine.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100259"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Could psychedelics be useful in the treatment of patients with personality disorder? A case report of psychotherapy with concomitant use of psychedelics 迷幻药对治疗人格障碍患者有用吗？心理治疗同时使用致幻剂一例报告

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-01-08 DOI: 10.1016/j.psycr.2025.100245

Martin Blay , Inès Benmakhlouf , Mario Speranza

{"title":"Could psychedelics be useful in the treatment of patients with personality disorder? A case report of psychotherapy with concomitant use of psychedelics","authors":"Martin Blay , Inès Benmakhlouf , Mario Speranza","doi":"10.1016/j.psycr.2025.100245","DOIUrl":"10.1016/j.psycr.2025.100245","url":null,"abstract":"<div><div>Psychotherapy enhanced by psychedelics has recently been found to be helpful for the treatment of several psychiatric disorders, notably depressive disorders. However, it has only been considered scarcely in patients suffering from personality disorders. Here, we report the case of a 37 years-old woman suffering from severe mixed personality disorder and ADHD. Alongside the beginning of her GPM-based psychotherapeutic treatment, and despite our concerns, she started closely monitored psychedelic micro-dosing, using products bought online, punctuated by occasional macro-dosing After one-year of this psychotherapy associated with concomitant independent use of psychedelics, paranoid, narcissistic and borderline personality dimensions were largely improved, as well as emotion regulation, impulsivity, mentalization abilities, and social functioning. Given the actual evidence regarding the efficacy of psychedelics to improve the latter four dimensions, given the patient's reported experience, and despite important limits, we make the hypothesis that the concomitant use of psychedelics has enhanced psychotherapy efficacy. Overall, this case asks the question of the potential usefulness of psychedelics associated with psychotherapy in patients with PD. Further pilot studies should be conducted on this issue.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100245"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A case of first-episode psychosis with catatonic features in an adolescent following THC use 青少年四氢大麻酚使用后首发精神病伴紧张性特征1例

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2025-01-22 DOI: 10.1016/j.psycr.2025.100248

Lily Porsa DO

引用次数: 0

The many faces of psilocybin-related psychosis: A case series 裸盖菇素相关精神病的多个方面：一个案例系列

Psychiatry research case reports Pub Date : 2025-06-01 Epub Date: 2024-12-07 DOI: 10.1016/j.psycr.2024.100243

Yumin Kim , Rachel Bigley , Aubrey DeVinney , Paul S. Nestadt

{"title":"The many faces of psilocybin-related psychosis: A case series","authors":"Yumin Kim , Rachel Bigley , Aubrey DeVinney , Paul S. Nestadt","doi":"10.1016/j.psycr.2024.100243","DOIUrl":"10.1016/j.psycr.2024.100243","url":null,"abstract":"<div><h3>Background</h3><div>Psilocybin use has been increasingly popular in the United States, and its use as a novel therapeutic treatment for psychiatric conditions has led to greater public acceptance as a recreational substance. Consequently, clinicians are faced with managing complications and adverse effects associated with psilocybin use.</div></div><div><h3>Basic Procedures/Main Findings</h3><div>We present three cases seen in a dual diagnosis inpatient psychiatry unit during a four-week period in 2023: Case 1: the case of intermittent psilocybin use associated with a particularly prolonged psychosis requiring treatment with higher doses and a longer course of neuroleptic medication; Case 2: the case of a short period of frequent psilocybin use culminating into increasing paranoia and a medically serious suicide attempt treated with neuroleptics; and Case 3: the case of long-term “microdosing” followed by mania-like symptoms including grandiosity, irritability, and physical aggression towards others, but with resolution of symptoms after discontinuing psilocybin use.</div></div><div><h3>Conclusions</h3><div>Amidst psilocybin's increasing prevalence and acceptance, clinicians are faced with managing the complications and adverse effects of psilocybin use with minimal guidelines or evidence. This case series aims to highlight varied presentations, management strategies, and treatment responses to contribute some insight into this unknown territory.</div></div>","PeriodicalId":74594,"journal":{"name":"Psychiatry research case reports","volume":"4 1","pages":"Article 100243"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143145893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0